8-K: Oragenics Secures $16.5 Million in Public Offering to Fund Concussion Drug Trials and Address Going Concern

Oragenics, Inc. has successfully closed a public offering, raising approximately $16.5 million in gross proceeds through the sale of Series H Convertible Preferred Stock and Warrants, primarily to fund its ONP-002 concussion clinical trials and repay a $3 million bridge note.

Summary

• Oragenics, Inc. consummated a public offering on July 2, 2025, issuing 660,000 shares of Series H Convertible Preferred Stock and Warrants to purchase an additional 660,000 shares of Preferred Stock.
• The combined public offering price for each unit (one share of Preferred Stock and one Warrant) was $25.00.
• The offering generated gross proceeds of approximately $16.5 million, with estimated net proceeds of approximately $15 million after deducting placement agent fees and other offering expenses.
• The Preferred Stock is convertible into Common Stock at an initial conversion price of $2.50 per share, subject to adjustment, and automatically converts on July 2, 2030.
• Warrants are immediately exercisable at $25.00 per share of Preferred Stock and expire on July 2, 2030.
• Holders of Preferred Stock are entitled to cumulative dividends at 9% per annum of the Stated Value ($25.00 per share), payable in Common Stock.
• The Company intends to use the net proceeds to fund ongoing ONP-002 concussion clinical trials, other related research and development activities, repay a $3 million bridge note, and for working capital and general corporate purposes.
• The Company's registration statement on Form S-1 (File No. 333-288225) was declared effective by the SEC on June 30, 2025.

Sentiment

Score: 6

Explanation: The capital raise is a significant positive, addressing immediate liquidity concerns and funding key clinical trials. However, the substantial dilution potential, lack of public market for preferred securities, and ongoing accumulated deficit temper the overall sentiment.

Positives

• Successfully raised approximately $15 million in net proceeds, providing crucial capital for operations.
• Proceeds are earmarked to advance the ONP-002 concussion clinical trials, a key therapeutic candidate.
• The offering allows for the repayment of a $3 million bridge note, reducing existing debt.
• The capital infusion addresses the previously disclosed substantial doubt about the Company's ability to continue as a going concern beyond Q3 2025.

Negatives

• The conversion of Preferred Stock into Common Stock, and subsequent exercise of Warrants, will dilute the percentage ownership of current common shareholders.
• The Certificate of Designation for the Preferred Stock contains anti-dilution provisions that could lower the Conversion Price if future securities are issued at a lower price, potentially leading to greater dilution.
• There is no established public trading market for the Preferred Stock or Warrants, and the Company does not intend to list them on any national securities exchange.
• The absence of a floor price on the conversion price means the total number of shares issuable upon conversion cannot be determined, which may depress the Common Stock price.

Risks

• Conversion of Series H Preferred Stock and exercise of Warrants will result in significant dilution to existing common shareholders.
• Anti-dilution provisions in the Preferred Stock's Certificate of Designation, which lack a floor price, could lead to further substantial dilution if the Company issues securities at prices below the current conversion price, potentially depressing the Common Stock price.
• The potential for conversion price adjustments may make it more difficult for the Company to raise additional equity capital while the Preferred Stock is outstanding.
• The Company has incurred recurring losses and negative cash flows from operations since inception, with an accumulated deficit of $219,003,165 as of March 31, 2025.
• There was substantial doubt about the Company's ability to continue as a going concern beyond the third quarter of 2025 prior to this offering.

Future Outlook

The Company plans to use the net proceeds from the offering to accelerate the clinical development of ONP-002, its lead intranasal drug candidate for mild traumatic brain injury (concussion), and support other related research and development activities. The capital is also intended to fund working capital and general corporate purposes, positioning Oragenics to advance its therapeutic pipeline.

Management Comments

• "We are pleased to have completed this transaction and are encouraged by the strong investor support, which we believe reflects growing confidence in our science and strategy."
• "We anticipate the net proceeds of this offering will allow us to accelerate the advancement of ONP-002 and position Oragenics as a leader in the treatment of concussion through novel intranasal delivery."

Industry Context

This offering by Oragenics, a development-stage biotechnology company, highlights the ongoing need for capital in the pharmaceutical industry, particularly for companies focused on novel drug delivery methods like intranasal therapeutics for neurological disorders. The funding of ONP-002 clinical trials aligns with the broader industry trend of investing in R&D for high-unmet-need areas such as mild traumatic brain injury (concussion). The reliance on public offerings for capital is common for clinical-stage biotech firms that have not yet generated significant revenues.

Comparison to Industry Standards

• The document does not provide specific comparable companies, projects, or results to assess the offering in the context of global benchmarks.

Stakeholder Impact

• Shareholders: Will experience significant dilution due to the conversion of Preferred Stock and exercise of Warrants, and potential further dilution from anti-dilution provisions.
• Investors (Purchasers in Offering): Gain exposure to Oragenics' future potential, particularly in neurological disorders, with preferred stock and warrant features.
• Employees: The capital raise provides financial stability, supporting continued employment and R&D activities.
• Creditors: Repayment of the $3 million bridge note improves the Company's debt profile.

Next Steps

• Advance the clinical development of ONP-002, the intranasal drug candidate for mild traumatic brain injury (concussion).
• Support other related research and development activities.
• Utilize funds for working capital and general corporate purposes.
• Maintain listing of Common Stock on NYSE American and apply to list all Common Shares underlying Warrants.

Key Dates

Recommendation

Keywords

Oragenics, OGEN, public offering, Series H Preferred Stock, Warrants, ONP-002, concussion, clinical trials, biotechnology, intranasal therapeutics, capital raise, SEC filing, Form 8-K, dilution, going concern, Dawson James Securities